Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
06:30am, Thursday, 17'th Jul 2025
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Will Increased Expenses Affect Bristol Myers' Performance?
09:46am, Wednesday, 16'th Jul 2025
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
01:52pm, Monday, 14'th Jul 2025
Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
09:13am, Monday, 14'th Jul 2025
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
11:00am, Friday, 11'th Jul 2025
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
05:36am, Friday, 11'th Jul 2025
Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends
08:45am, Thursday, 10'th Jul 2025
The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focu
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
03:01am, Thursday, 10'th Jul 2025
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, sin
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Wednesday, 09'th Jul 2025
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day.
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
10:20am, Wednesday, 09'th Jul 2025
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro
12:36pm, Tuesday, 08'th Jul 2025
My contrarian yield-based strategy spotlights high-yield 'ReFa/Ro Dogs' with analyst forecasts suggesting 19-33% net gains by June 2026. All top ten ReFa/Ro Dogs offer annual dividends from $1,000 inv
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
10:41am, Tuesday, 08'th Jul 2025
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
2 Wonderful Dividends At Bargain Basement Prices
11:45am, Monday, 07'th Jul 2025
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
10:01am, Monday, 07'th Jul 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income
07:31am, Monday, 07'th Jul 2025
Blue-chip dividend stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
